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Background: Oral corticosteroid prescriptions are often used in clinical studies as an indicator of asthma exacerbations.
However, there is rarely the ability to link a prescription to its associated diagnosis. The objective of this study was to
characterize patterns of oral corticosteroid prescription orders for asthma patients using an electronic health record
database, which links each prescription order to the diagnosis assigned at the time the order was placed.
Methods: This was a retrospective cohort study of the electronic health records of asthma patients enrolled in the
Geisinger Health System from January 1, 2001 to August 23, 2010. Eligible patients were 12–85 years old, had a primary
care physician in the Geisinger Health System, and had asthma. Each oral corticosteroid order was classified as being
prescribed for an asthma-related or non-asthma-related condition based on the associated diagnosis. Asthma-related
oral corticosteroid use was classified as either chronic or acute. In patient-level analyses, we determined the number of
asthma patients with asthma-related and non-asthma-related prescription orders and the number of patients with
acute versus chronic use. Prescription-level analyses ascertained the percentages of oral corticosteroid prescription
orders that were for asthma-related and non-asthma-related conditions.
Results: Among the 21,199 asthma patients identified in the electronic health record database, 15,017 (70.8%) had an
oral corticosteroid prescription order. Many patients (N = 6,827; 45.5%) had prescription orders for both asthma-related
and non-asthma-related conditions, but some had prescription orders exclusively for asthma-related (N = 3,450; 23.0%)
or non-asthma-related conditions (N = 4,740; 31.6%). Among the patients receiving a prescription order, most (87.5%)
could be classified as acute users. A total of 60,355 oral corticosteroid prescription orders were placed for the asthma
patients in this study—31,397 (52.0%) for non-asthma-related conditions, 24,487 (40.6%) for asthma-related conditions,
and 4,471 (7.4%) for both asthma-related and non-asthma-related conditions.
Conclusions: Oral corticosteroid prescriptions for asthma patients are frequently ordered for conditions unrelated to
asthma. A prescription for oral corticosteroids may be an unreliable marker of asthma exacerbations in retrospective
studies utilizing administrative claims data. Investigators should consider co-morbid conditions for which oral
corticosteroid use may also be indicated and/or different criteria for assessing oral corticosteroid use for asthma.
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The prevention of exacerbations of asthma symptoms is
recognized in treatment guidelines as a key component
of controlling asthma [1]. An exacerbation is broadly de-
fined as an acute worsening of asthma symptoms requir-
ing a transient change in treatment. There is, however,
neither a uniformly accepted definition of an exacerba-
tion nor a consensus on how an exacerbation should be
measured [2].
The American Thoracic Society and European Re-
spiratory Society (ATS/ERS) recommended in an official
statement that the definition of a severe asthma exacer-
bation should include the use of systemic corticosteroids
[2]. However, this definition applies only in clinical trials
[2], and subjects enrolled in major randomized clinical
trials of asthma medications are not representative of
asthma patients in the general population [3]. Asthma
patients in the general population are often studied
retrospectively by way of administrative data sets in
which surrogate variables are used as a measure of
exacerbations.
Observational studies of administrative data sets have
used oral corticosteroid prescriptions, either alone or as
part of a composite measure with asthma-related emer-
gency department visits and inpatient stays, as a meas-
ure of asthma exacerbations [4-10]. The definitions of an
exacerbation in these types of studies vary extensively.
Finkelstein et al. used the “dispensing of an oral steroid
preparation as a proxy for the occurrence of an acute ex-
acerbation” [11]. Friedman defined an asthma exacerba-
tion as an episode requiring “hospitalization, treatment
in an emergency room, or an outpatient visit” where the
patient “received nebulized medication or a prescription
for oral corticosteroids” [12]. More recent studies have
been more explicit in terms of days’ supply of oral cor-
ticosteroid and the timing of a prescription relative to an
outpatient visit [7,13,14]. However, the lack of a stan-
dardized definition of exacerbations limits the applicability
of observational findings to clinical practice.
The NIH and the Agency for Healthcare Research and
Quality have drafted recommendations for the standardi-
zation of asthma outcome measures for both clinical trials
and observational studies [15]. The recommendations de-
fine an exacerbation as a “worsening of asthma requiring
the use of systemic corticosteroids to prevent a serious
outcome” [16]. For exacerbations in patients twelve years
of age and older, the core outcome measures for observa-
tional studies are the use of systemic corticosteroids (oral,
injected, or IV), hospitalization, and emergency depart-
ment (or urgent care) visits for asthma [16].
One limitation of using oral corticosteroids as a mea-
sure of asthma exacerbations is that administrative claims
data sets typically do not link a claim for a prescription to
the diagnosis prompting the prescription, making itdifficult to determine whether a given oral corticosteroid
prescription was written for an asthma exacerbation or for
a condition unrelated to the patient’s asthma. Oral corti-
costeroids can be prescribed for variety of conditions
unrelated to asthma, including systemic inflammatory
diseases and pain syndromes. Integrated health care deliv-
ery systems that maintain electronic health records of all
patient encounters contain the information needed to link
a prescription order to the diagnosis assigned at the time
the order was placed. Thus, with an electronic health
record database, it is possible to determine whether an
oral corticosteroid prescription was ordered for an asthma
exacerbation or for some other reason.
The objective of this study was to use the electronic
health records of an integrated health care delivery sys-
tem to determine the medical diagnoses associated with
oral corticosteroid prescriptions ordered for asthma pa-
tients, and thus to characterize the use of oral corticoste-
roid prescriptions as a measure of asthma exacerbations in
a primary care setting.
Methods
Study design and setting
This study was a retrospective cohort analysis of oral cor-
ticosteroid use in a population of primary care asthma pa-
tients who are members of the Geisinger Health System,
an integrated health care delivery system that serves resi-
dents in central and northeastern Pennsylvania. The
Geisinger Health System includes the Geisinger Clinic, a
network of 37 community-based offices staffed by primary
care physicians. The Geisinger Clinic network provides
primary care to over 400,000 patients. All network of-
fices have used the EpicCare™ electronic health record
(EHR) since 2001. The study period was January 1, 2001
to August 23, 2010.
Data sources
Geisinger’s longitudinal EHR served as the data source
for this study. The EHR includes a patient’s “problem
list”, a dynamic and comprehensive list of all of a patient’s
medical problems. Each medical problem is entered into
the EHR by a provider (e.g., nurse or physician) using a
structured vocabulary, the terms of which are automati-
cally linked to the International Classification of Disease
(ICD-9) code. Similarly, all patient encounters (e.g., office
visits) are assigned at least one diagnostic ICD-9 code by
the provider. These provider-entered “encounter diagnosis
codes” summarize the specific medical problems ad-
dressed during the encounter and are used also for billing
purposes. Whereas the problem list is a comprehensive,
current list of all of a patient’s medical problems and can
change over time as problems are resolved and/or new
problems are identified, encounter diagnoses are
encounter-specific—once assigned to an encounter, they
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lem is added to or removed from the problem list.
At all Geisinger Clinic offices, medication prescrip-
tions must be ordered electronically via the EHR. Each
order includes the following items: order date; medica-
tion name, dose, and class; prescribed quantity; allowed
number of refills; and free-text instructions on dosing
and administration (the medication “sig”). In addition,
the provider is required to assign one or more diagnostic
codes that summarize the conditions the medication is
intended to treat. As with the problem list and encoun-
ter codes, the reason for the prescription order is en-
tered using a structured vocabulary and mapped to an
underlying ICD-9 code.
Patient sample
Potentially eligible patients were identified by searching
Geisinger’s EHR. The sampling frame included all pa-
tients aged 12 to 85 with a primary care provider at one
of the Geisinger clinics and an indication of having
asthma during the study period. Patients were classified
as having asthma if they had any one of the following: ≥2
office visits within a 12-month period with an associated
ICD-9 code of 493.xx, an active asthma diagnosis on their
problem list during the study period, or a prescription
order with an associated asthma diagnosis (493.xx).
Patients were excluded if they had ICD-9 codes for
chronic obstructive pulmonary disease (491.xx, 492.xx),
bronchiectasis (494.xx), chronic airway obstruction (not
otherwise specified; 406.xx), cystic fibrosis (748.4), or
bronchopulmonary dysplasia (770.7) on their problem list
or in an encounter diagnosis. The study was approved
with a waiver of patient consent by the Geisinger Health
System institutional review board (Ref: 2010-0297).
Oral corticosteroid prescriptions analysis
After identifying all eligible asthma patients, we identi-
fied every oral corticosteroid prescription ordered for an
asthma patient during the study period. Each order was
classified on two dimensions: relation to asthma (yes or
no) and pattern (acute or chronic). To determine
whether an oral corticosteroid order was asthma-related,
we relied on the diagnosis code assigned to the order by
the provider. In collaboration with clinical experts, we
classified ICD-9 codes 493.00 (extrinsic asthma, unspeci-
fied), 493.02 (extrinsic asthma with exacerbation), 493.90
(unspecified asthma), and 493.92 (unspecified asthma,
with exacerbation) as asthma-related; all other codes
were classified as non-asthma-related.
Whether the pattern of oral corticosteroid orders was
acute or chronic was determined on the basis of the
order information in the EHR (the details of which were
described above). The definitions of acute and chronic
use of oral corticosteroids were derived after investigatorreview (FAR and LN) of a random sample of prescrip-
tion orders. The initial definition was then applied to a
subsequent sample of orders for validation. The final
definition used for the analysis (described below) was
endorsed through a third sample of orders reviewed
alongside the proposed definition by a pulmonary phys-
ician with the Geisinger Health System. An acute order
was defined as (1) an order with zero refills or (2) an
order quantity <30. A chronic order was defined as an
order quantity ≥30 with one or more refills. These
resulting criteria were then applied to all oral cortico-
steroid orders for patients in the study population.
Data analysis
Because a single patient can have multiple prescription
orders, separate descriptive analyses were conducted
using, first, the patient, and second, the prescription
order, as the unit of analysis. Patient-level analyses in-
cluded: the number of patients with asthma, the number
of asthma patients with asthma-related and non-asthma-
related oral corticosteroid orders, and the number of
asthma patients with patterns of oral corticosteroid or-
ders consistent with acute versus chronic use.
Prescription-level analyses included the total number of
oral corticosteroid orders for asthma patients and the
percentages of those orders written for asthma-related
versus non-asthma-related conditions. Differences in
acute and chronic order patterns along with diagnoses
associated with OCS orders were examined for adoles-
cents (ages 12–17 years), adults (18–44 and 45–64 years)
and elderly patients (≥65 years).
Results
Characteristics of the asthma patient population
A total of 21,199 unique asthma patients were identified
in the EHR database for the study period and met the
study inclusion criteria (Figure 1; Table 1). The mean
age was 39.5 years, and majorities of the patients were
female (67.9%) and Caucasian (94.3%). The total average
number of office visits per patient was 36.5, while the
average number of asthma-related office visits was 8.3.
Similarly, the average number of asthma-related emer-
gency department visits and inpatient visits (1.6 and 1.5,
respectively) was only a fraction of the total number of
each type of visit (3.6 and 3.5, respectively). The most
prevalent comorbidities, present in about half the study
population, were acute sinusitis (58.6%), allergic rhinitis
(56.1%), and acute bronchitis (48.8%).
Asthma patients with oral corticosteroid prescription
orders
Of the 21,199 asthma patients, 15,017 (70.8%) had a pre-
scription order for an oral corticosteroid. Among all pa-
tients with an oral corticosteroid prescription order,
Figure 1 Number and type of oral corticosteroid prescription orders for asthma patients. OCS, oral corticosteroid.
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related condition, 4,740 (31.6%) had orders exclusively
for a non-asthma-related condition, and 6,827 (45.5%)
had orders for both asthma-related and non-asthma-related
conditions. Most asthma patients (87.5%) were classified
as acute users regardless of age (Table 2).Table 1 Characteristics of the asthma patient populationa
Age 12–17
N = 3,496
Age, years (mean, SD) 14.3 1.7 40.
Female 1,879 54% 10,8
Caucasian 3,181 91% 14,5
Encounters, per patient (mean, SD)b
Total office visits 27.6 23.1 36.
Asthma-related office visits 6.3 5.4 8.5
Total ED visits 3.5 5.1 3.8
Asthma-related ED visits 1.7 1.1 1.5
Total inpatient visits 2.7 4.1 3.1
Asthma-related inpatient visits 1.5 1.3 1.5
Comorbidities
Acute sinusitis 2,129 61% 9,35
Allergic rhinitis 2,193 63% 8,73
Acute bronchitis 1,167 33% 7,93
Allergic rhinorrhea 1,719 49% 6,58
Acute upper respiratory conditions 1,772 51% 5,70
Gastroesophageal reflux disease 764 22% 6,15
Chronic sinusitis 376 11% 2,45
Chronic otitis media 755 22% 1,97
Pneumonia 312 9% 1,52
Current Smoker 515 15% 2,23
ED emergency department, SD standard deviation.
aData are presented as N (%) unless otherwise indicated.
bOffice visits were calculated over the period 2001–2010, ED visits and inpatient visOral corticosteroid prescription orders for asthma patients
A total of 60,355 oral corticosteroid prescription orders
were placed for the asthma patients in this study—
24,487 (40.6%) for an asthma-related condition, 31,397
(52.0%) for non-asthma-related conditions, and 4,471
(7.4%) for both asthma-related and non-asthma-relatedAge 18–64 Age ≥ 65 Total
N = 15,352 N = 2,351 N = 21,199
1 12.4 72.8 5.8 39.5 18.5
59 71% 1,650 70% 14,394 67.9%
00 94% 2,304 98% 19,990 94.3%
6 31.7 48.6 35.4 36.5 31.4
8.0 10.3 9.8 8.3 7.9
7.9 2.8 4.5 3.6 7.3
1.4 1.4 1.1 1.6 1.6
4.4 5.1 7.1 3.5 5.1
1.4 1.4 1.1 1.5 1.4
3 61% 938 40% 12,420 58.6%
3 57% 957 41% 11,883 56.1%
5 52% 1,248 53% 10,350 48.8%
0 43% 666 28% 8,965 42.3%
0 37% 662 28% 8,134 38.4%
9 40% 1,142 49% 8,065 38.0%
8 16% 297 13% 3,131 14.8%
7 13% 131 6% 2,863 13.5%
3 10% 479 20% 2,314 10.9%
4 15% 52 2% 2,801 13.2%
its were calculated over 2004–2010.
Table 2 Number of asthma patients with oral corticosteroid order patterns classified as acute or chronic
Age 12–17 Age 18–44 Age 45–64 Age ≥ 65 Total
(N = 1,995) (N = 6,891) (N = 4,464) (N = 1,667) (N = 15,017)
Acute 1,919 (96.2%) 6,249 (90.7%) 3,703 (83%) 1,263 (75.8%) 13,134 (87.5%)
Chronic 76 (3.8%) 642 (9.3%) 761 (17%) 404 (24.2%) 1,883 (12.5%)
Allen-Ramey et al. Allergy, Asthma & Clinical Immunology 2013, 9:27 Page 5 of 7
http://www.aacijournal.com/content/9/1/27conditions (Figure 1). Among patients with one or more
prescriptions for oral corticosteroids, the median num-
ber (range) of oral corticosteroid prescription orders per
patient was 2.0 (1–103) for asthma-related conditions
and 2.0 (1–72) for conditions unrelated to asthma. The
most common diagnoses associated with oral cortico-
steroid prescription orders among patients with asthma
are listed in Table 3.
Discussion
In this population of primary care patients, over half
(61.5%) of the oral corticosteroid prescriptions written
for patients with asthma were prescribed for conditions
unrelated to asthma (Table 3). This result suggests that,
without an associated diagnosis, a prescription for an
oral corticosteroid is not by itself an adequate marker
for an asthma exacerbation in patients with asthma (but
without other chronic respiratory diseases). This is con-
sistent with evidence that a systemic corticosteroid pre-
scription is poorly predictive of a diagnosis of asthma [17].
Oral corticosteroid use meets three of the four re-
quirements for a core outcome measure in the NIH
draft recommendations: it is clinically relevant, feasible,Table 3 Diagnoses associated with oral corticosteroid orders
Diagnosis category Age 12-17 Age 18-44
Counta Percentb Counta Percentb
Asthma-related 3185 4.2% 13463 17.9%
Otherc 661 0.9% 3987 5.3%
Other upper respiratoryd 1008 1.3% 4522 6.0%
Pain syndrome 316 0.4% 3505 4.7%
Missing 368 0.5% 2168 2.9%
Allergic reaction 682 0.9% 2043 2.7%
Systematic inflammatory 115 0.2% 1028 1.4%
Other lower respiratory 255 0.3% 775 1.0%
Other skin 177 0.2% 695 0.9%
Neoplasms 34 0.0% 194 0.3%
Infection 18 0.0% 223 0.3%
Unsure 11 0.0% 44 0.1%
COPD 1 0.0% 6 0.0%
aColumn total does not equal the total number of distinct orders because each ind
category represents a distinct count of orders.
bPercentages were calculated relative to the total number of prescription diagnoses
asthma patients.
cOther includes included pain syndrome, endocrine, head and neck disorders, hema
dOther upper respiratory includes rhinitis (allergic and chronic), chronic sinusitis, naand enables comparison across studies [15]. The fourth
requirement, evidence of validity, requires further re-
search. In particular, the factors that contribute to pa-
tient and clinician decisions to use oral corticosteroids
need to be investigated [16]. This study is, to our know-
ledge, the first to report the frequency with which
asthma patients receive oral corticosteroids for condi-
tions unrelated to asthma.
Across all age groups in this sample, most asthma pa-
tients were acute users of oral corticosteroids. A minority
(12.5% overall) were considered chronic users. However,
frequent exacerbations are difficult to distinguish from
poorly controlled persistent asthma. The chronic asthma-
related use by some patients—the number of prescriptions
ranged up to 103, i.e., 8 years of 30-day prescriptions—
may represent poor control of persistent asthma due to in-
adequate use of long-term control medications (inhaled
corticosteroids, etc.) rather than exacerbations. (‘Chronic’
use of systemic corticosteroids is an option to control se-
vere asthma [1]). Thus, only the acute use (which was
87.5% of all use) can reliably be related to exacerbations.
The principal limitation of this analysis is uncertainty
about the diagnosis associated with prescription orders.for patients with asthma
Age 45-64 Age ≥ 65 Total
Counta Percentb Counta Percentb Counta Percentb
9356 12.4% 2954 3.9% 28958 38.5%
4251 5.6% 1509 2.0% 10408 13.8%
3130 4.2% 795 1.1% 9455 12.6%
3196 4.2% 1100 1.5% 8117 10.8%
1635 2.2% 867 1.2% 5038 6.7%
1258 1.7% 364 0.5% 4347 5.8%
1670 2.2% 1264 1.7% 4077 5.4%
611 0.8% 271 0.4% 1912 2.5%
453 0.6% 157 0.2% 1482 2.0%
350 0.5% 220 0.3% 798 1.1%
277 0.4% 39 0.1% 557 0.7%
34 0.0% 20 0.0% 109 0.1%
13 0.0% 14 0.0% 34 0.0%
ividual order can potentially have multiple diagnosis categories. Each diagnosis
(N = 75,292) associated with all OCS medication orders (N = 60,355) among
tologic, infections and autoimmune conditions.
sal polyps, tonsillitis and other conditions of the septum and larynx.
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each prescription order, but there is no quality check to
ensure that the selected code is accurate. As a result,
misclassification of asthma-related versus non-asthma-
related prescription orders might occur. A small number
(9.4%) of the oral corticosteroid orders in the EHR did
not have an associated diagnosis, and these were catego-
rized as being non-asthma-related in our analysis. Given
the potential for orders classified as upper respiratory
but not asthma-related to alter our results, we con-
ducted a sensitivity analysis classifying bronchitis as an
asthma-related condition. The resulting proportion of
oral corticosteroid orders that were not asthma-related
declined from 61.5% to 55.0%, which still supports our
conclusions. In addition, the appearance of ‘asthma’ in a
patient’s problem list in an EHR has not been validated
as a means of diagnosing asthma. Hence, it is possible
that patients identified as having asthma solely on the
basis of an entry in the patient’s problem list did not ac-
tually have asthma. The validity of the use of health ad-
ministrative databases to identify asthma patients,
however, has been studied. In this study, patients were
classified as having asthma if they had ≥2 office visits
within a 12-month period with an associated ICD-9 code
for asthma. Gershon et al. (2009) reported that a similar
algorithm (≥2 ambulatory care visits and/or ≥1 hos-
pitalization for asthma in a 2 year period) had a sensitivity
and specificity of 83.8% and 76.5%, respectively, with
expert chart review as the reference standard [18]. The
positive predictive value was 61.5% (but 72.5% with the
primary care physician chart diagnosis as reference
standard) [18].
This analysis did not account for the chronology of
the oral corticosteroid prescription with respect to exac-
erbations. Unless oral corticosteroid orders were
recorded only after a diagnosis of asthma was entered
into the EHR, it is possible that patients did not have
asthma when the oral corticosteroid was prescribed.
One way to improve this study design is to define the
chronology of the prescription with respect to the
asthma-related outpatient visit, as was done by Schatz
et al., who noted that some oral corticosteroids may be
prescribed prophylactically rather than for a current ex-
acerbation [7]. Another way is to impose a limit on the
time between an outpatient visit for asthma and a pre-
scription order related to asthma (e.g., ≤5 days), as was
done by Lee et al. [19]. A second level of stringency
could include defining the days’ supply of oral cortico-
steroid, as was done in two recent studies that defined
exacerbations by oral corticosteroid prescriptions for
<22 days’ supply [13,14]. These approaches combined
would ensure that the prescription was truly for an acute
exacerbation and not the result of inadequate control of
persistent asthma symptoms.Conclusions
In this population of primary care patients, over half of
the oral corticosteroid prescriptions for patients with
asthma were for conditions unrelated to asthma. This
finding has implications for how oral corticosteroid pre-
scriptions should be interpreted in future observational
research, particularly retrospective studies. In studies
utilizing administrative claims data, a prescription for
oral corticosteroids may be an unreliable marker of
asthma exacerbations. Investigators should consider co-
morbid conditions for which oral corticosteroid use may
also be indicated. The accuracy of an oral corticosteroid
prescription as a marker of an exacerbation should be
evaluated, and algorithms to identify oral corticosteroid
prescriptions ordered for acute asthma episodes in ad-
ministrative claims data should be developed and
validated.
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